Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients

The COSMOS study

Jose Luis Fernandez-Martin, Pablo Martinez-Camblor, Maria Paula Dionisi, Jürgen Floege, Markus Ketteler, Gerard London, Francesco Locatelli, Jose Luis Gorriz, Boleslaw Rutkowski, Anibal Ferreira, Willem Jan Bos, Adrian Covic, Minerva Rodriguez-Garcia, Jose Emilio Sanchez, Diego Rodriguez-Puyol, Jorge B. Cannata-Andia

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background Abnormalities in serum phosphorus, calcium and parathyroid hormone (PTH) have been associated with poor survival in haemodialysis patients. This COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) analysis assesses the association of high and low serum phosphorus, calcium and PTH with a relative risk of mortality. Furthermore, the impact of changes in these parameters on the relative risk of mortality throughout the 3-year follow-up has been investigated. Methods COSMOS is a 3-year, multicentre, open-cohort, prospective study carried out in 6797 adult chronic haemodialysis patients randomly selected from 20 European countries. Results Using Cox proportional hazard regression models and penalized splines analysis, it was found that both high and low serum phosphorus, calcium and PTH were associated with a higher risk of mortality. The serum values associated with the minimum relative risk of mortality were 4.4 mg/dL for serum phosphorus, 8.8 mg/dL for serum calcium and 398 pg/mL for serum PTH. The lowest mortality risk ranges obtained using as base the previous values were 3.6-5.2 mg/dL for serum phosphorus, 7.9-9.5 mg/dL for serum calcium and 168-674 pg/mL for serum PTH. Decreases in serum phosphorus and calcium and increases in serum PTH in patients with baseline values of >5.2 mg/dL (phosphorus), >9.5 mg/dL (calcium) and <168 pg/mL (PTH), respectively, were associated with improved survival. Conclusions COSMOS provides evidence of the association of serum phosphorus, calcium and PTH and mortality, and suggests survival benefits of controlling chronic kidney disease-mineral and bone disorder biochemical parameters in CKD5D patients.

Original languageEnglish
Pages (from-to)1542-1551
Number of pages10
JournalNephrology Dialysis Transplantation
Volume30
Issue number9
DOIs
Publication statusPublished - 1 Sep 2015

Fingerprint

Minerals
Renal Dialysis
Bone and Bones
Parathyroid Hormone
Survival
Phosphorus
Serum
Calcium
Mortality
Chronic Kidney Disease-Mineral and Bone Disorder
Secondary Hyperparathyroidism
Proportional Hazards Models
Multicenter Studies
Observational Studies
Cohort Studies
Prospective Studies

Keywords

  • Calcium
  • chronic kidney disease
  • CKD-MBD
  • cosmos
  • hemodialysis
  • phosphorous
  • PTH
  • survival

Cite this

Fernandez-Martin, J. L., Martinez-Camblor, P., Dionisi, M. P., Floege, J., Ketteler, M., London, G., ... Cannata-Andia, J. B. (2015). Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study. Nephrology Dialysis Transplantation, 30(9), 1542-1551. https://doi.org/10.1093/ndt/gfv099
Fernandez-Martin, Jose Luis ; Martinez-Camblor, Pablo ; Dionisi, Maria Paula ; Floege, Jürgen ; Ketteler, Markus ; London, Gerard ; Locatelli, Francesco ; Gorriz, Jose Luis ; Rutkowski, Boleslaw ; Ferreira, Anibal ; Bos, Willem Jan ; Covic, Adrian ; Rodriguez-Garcia, Minerva ; Sanchez, Jose Emilio ; Rodriguez-Puyol, Diego ; Cannata-Andia, Jorge B. / Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients : The COSMOS study. In: Nephrology Dialysis Transplantation. 2015 ; Vol. 30, No. 9. pp. 1542-1551.
@article{62be4317bcc14a9dbfe76acc1b42f163,
title = "Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study",
abstract = "Background Abnormalities in serum phosphorus, calcium and parathyroid hormone (PTH) have been associated with poor survival in haemodialysis patients. This COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) analysis assesses the association of high and low serum phosphorus, calcium and PTH with a relative risk of mortality. Furthermore, the impact of changes in these parameters on the relative risk of mortality throughout the 3-year follow-up has been investigated. Methods COSMOS is a 3-year, multicentre, open-cohort, prospective study carried out in 6797 adult chronic haemodialysis patients randomly selected from 20 European countries. Results Using Cox proportional hazard regression models and penalized splines analysis, it was found that both high and low serum phosphorus, calcium and PTH were associated with a higher risk of mortality. The serum values associated with the minimum relative risk of mortality were 4.4 mg/dL for serum phosphorus, 8.8 mg/dL for serum calcium and 398 pg/mL for serum PTH. The lowest mortality risk ranges obtained using as base the previous values were 3.6-5.2 mg/dL for serum phosphorus, 7.9-9.5 mg/dL for serum calcium and 168-674 pg/mL for serum PTH. Decreases in serum phosphorus and calcium and increases in serum PTH in patients with baseline values of >5.2 mg/dL (phosphorus), >9.5 mg/dL (calcium) and <168 pg/mL (PTH), respectively, were associated with improved survival. Conclusions COSMOS provides evidence of the association of serum phosphorus, calcium and PTH and mortality, and suggests survival benefits of controlling chronic kidney disease-mineral and bone disorder biochemical parameters in CKD5D patients.",
keywords = "Calcium, chronic kidney disease, CKD-MBD, cosmos, hemodialysis, phosphorous, PTH, survival",
author = "Fernandez-Martin, {Jose Luis} and Pablo Martinez-Camblor and Dionisi, {Maria Paula} and J{\"u}rgen Floege and Markus Ketteler and Gerard London and Francesco Locatelli and Gorriz, {Jose Luis} and Boleslaw Rutkowski and Anibal Ferreira and Bos, {Willem Jan} and Adrian Covic and Minerva Rodriguez-Garcia and Sanchez, {Jose Emilio} and Diego Rodriguez-Puyol and Cannata-Andia, {Jorge B.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1093/ndt/gfv099",
language = "English",
volume = "30",
pages = "1542--1551",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press (OUP)",
number = "9",

}

Fernandez-Martin, JL, Martinez-Camblor, P, Dionisi, MP, Floege, J, Ketteler, M, London, G, Locatelli, F, Gorriz, JL, Rutkowski, B, Ferreira, A, Bos, WJ, Covic, A, Rodriguez-Garcia, M, Sanchez, JE, Rodriguez-Puyol, D & Cannata-Andia, JB 2015, 'Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study', Nephrology Dialysis Transplantation, vol. 30, no. 9, pp. 1542-1551. https://doi.org/10.1093/ndt/gfv099

Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients : The COSMOS study. / Fernandez-Martin, Jose Luis; Martinez-Camblor, Pablo; Dionisi, Maria Paula; Floege, Jürgen; Ketteler, Markus; London, Gerard; Locatelli, Francesco; Gorriz, Jose Luis; Rutkowski, Boleslaw; Ferreira, Anibal; Bos, Willem Jan; Covic, Adrian; Rodriguez-Garcia, Minerva; Sanchez, Jose Emilio; Rodriguez-Puyol, Diego; Cannata-Andia, Jorge B.

In: Nephrology Dialysis Transplantation, Vol. 30, No. 9, 01.09.2015, p. 1542-1551.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients

T2 - The COSMOS study

AU - Fernandez-Martin, Jose Luis

AU - Martinez-Camblor, Pablo

AU - Dionisi, Maria Paula

AU - Floege, Jürgen

AU - Ketteler, Markus

AU - London, Gerard

AU - Locatelli, Francesco

AU - Gorriz, Jose Luis

AU - Rutkowski, Boleslaw

AU - Ferreira, Anibal

AU - Bos, Willem Jan

AU - Covic, Adrian

AU - Rodriguez-Garcia, Minerva

AU - Sanchez, Jose Emilio

AU - Rodriguez-Puyol, Diego

AU - Cannata-Andia, Jorge B.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background Abnormalities in serum phosphorus, calcium and parathyroid hormone (PTH) have been associated with poor survival in haemodialysis patients. This COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) analysis assesses the association of high and low serum phosphorus, calcium and PTH with a relative risk of mortality. Furthermore, the impact of changes in these parameters on the relative risk of mortality throughout the 3-year follow-up has been investigated. Methods COSMOS is a 3-year, multicentre, open-cohort, prospective study carried out in 6797 adult chronic haemodialysis patients randomly selected from 20 European countries. Results Using Cox proportional hazard regression models and penalized splines analysis, it was found that both high and low serum phosphorus, calcium and PTH were associated with a higher risk of mortality. The serum values associated with the minimum relative risk of mortality were 4.4 mg/dL for serum phosphorus, 8.8 mg/dL for serum calcium and 398 pg/mL for serum PTH. The lowest mortality risk ranges obtained using as base the previous values were 3.6-5.2 mg/dL for serum phosphorus, 7.9-9.5 mg/dL for serum calcium and 168-674 pg/mL for serum PTH. Decreases in serum phosphorus and calcium and increases in serum PTH in patients with baseline values of >5.2 mg/dL (phosphorus), >9.5 mg/dL (calcium) and <168 pg/mL (PTH), respectively, were associated with improved survival. Conclusions COSMOS provides evidence of the association of serum phosphorus, calcium and PTH and mortality, and suggests survival benefits of controlling chronic kidney disease-mineral and bone disorder biochemical parameters in CKD5D patients.

AB - Background Abnormalities in serum phosphorus, calcium and parathyroid hormone (PTH) have been associated with poor survival in haemodialysis patients. This COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) analysis assesses the association of high and low serum phosphorus, calcium and PTH with a relative risk of mortality. Furthermore, the impact of changes in these parameters on the relative risk of mortality throughout the 3-year follow-up has been investigated. Methods COSMOS is a 3-year, multicentre, open-cohort, prospective study carried out in 6797 adult chronic haemodialysis patients randomly selected from 20 European countries. Results Using Cox proportional hazard regression models and penalized splines analysis, it was found that both high and low serum phosphorus, calcium and PTH were associated with a higher risk of mortality. The serum values associated with the minimum relative risk of mortality were 4.4 mg/dL for serum phosphorus, 8.8 mg/dL for serum calcium and 398 pg/mL for serum PTH. The lowest mortality risk ranges obtained using as base the previous values were 3.6-5.2 mg/dL for serum phosphorus, 7.9-9.5 mg/dL for serum calcium and 168-674 pg/mL for serum PTH. Decreases in serum phosphorus and calcium and increases in serum PTH in patients with baseline values of >5.2 mg/dL (phosphorus), >9.5 mg/dL (calcium) and <168 pg/mL (PTH), respectively, were associated with improved survival. Conclusions COSMOS provides evidence of the association of serum phosphorus, calcium and PTH and mortality, and suggests survival benefits of controlling chronic kidney disease-mineral and bone disorder biochemical parameters in CKD5D patients.

KW - Calcium

KW - chronic kidney disease

KW - CKD-MBD

KW - cosmos

KW - hemodialysis

KW - phosphorous

KW - PTH

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84940704357&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfv099

DO - 10.1093/ndt/gfv099

M3 - Article

VL - 30

SP - 1542

EP - 1551

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 9

ER -